With $18M In Series B Funds, Edimer To Test Protein-Replacement Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Building on Swiss research, the biotech hopes to develop the first therapy for X-linked hypohidrotic ectodermal dysplasia, a genetic mutation that can impact development of teeth, hair and skin. After Phase I testing in adults, Edimer now plans to test EDI200 in six to 10 infants in Phase II.